STAT Inhibitors Pipeline Insights 2019

"STAT Inhibitors- Pipeline Insights, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across STAT Inhibitors. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 15+ active products with more than 8 companies involved. Two of the key players include Napabucasin of Boston Biomedical and Bardoxolone methyl of Reata Pharmaceuticals.
Products covered by Phase
• Phase III, Phase II, Phase I
• IND
• Pre-clinical & Discovery
• Inactive (Dormant and Discontinued)

Overview of pipeline development activities for STAT Inhibitors
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
Therapeutic segmentation of products for STAT Inhibitors
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.
Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• Provides an overview of therapeutic pipeline activity for STAT Inhibitors across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of STAT Inhibitors therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
• Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
• Coverage of dormant and discontinued pipeline projects across STAT Inhibitors
Reasons to Buy
• Establish a comprehensive understanding of the current pipeline scenario across STAT Inhibitors to formulate effective R&D strategies
• Assess challenges and opportunities that influence STAT Inhibitors R&D
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
• Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for STAT Inhibitors to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive and discontinued drugs

Executive Summary
Overview
Introduction

Structure of STAT Protein
Mechanism of Action
STAT Inhibitor Mechanism
Functions of STAT Proteins
Diseases
Pipeline Therapeutics
Competitive Landscape
Comparative Analysis
Late Stage Products (Phase III)
Comparative Analysis
Napabucasin: Boston Biomedical
Product Description
Research and Development
Product Development Activities
The list continues…..
Mid Stage Products (Phase II)
Comparative Analysis
OPB-111077: Otsuka
Product Description
Research and Development
The list continues…..
Early Stage Products (Phase I & IND)
Comparative Analysis
Pre-clinical and Discovery Products
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dormant and Discontinued Products
Comparative Analysis
Appendix

List of Tables

Table 1: Total Products for STAT Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical and Discovery Stage Products
Table 6: Assessment by Mono Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Inactive Products
Table 12: Dormant Products
Table 13: Discontinued Products

List of Figures

Figure 1: STAT protein structure
Figure 2: Total Products for STAT Inhibitors
Figure 3: Late Stage Products (Phase III)
Figure 4: Mid Stage Products (Phase II)
Figure 5: Early Stage Products (Phase I)
Figure 6: Pre-clinical and Discovery Stage Products
Figure 7: Assessment by Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
Figure 13: Dormant Products
Figure 14: Discontinued Products